NCT03880435View on ClinicalTrials.gov

HYALOBARRIER® GEL ENDO Versus no HYALOBARRIER® GEL ENDO Following Operative Hysteroscopy for Improving Reproductive Outcome in Women With Intrauterine Pathology Wishing to Become Pregnant

NAActive, not recruitingINTERVENTIONAL
Enrollment

419

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

June 30, 2024

Study Completion Date

May 31, 2025

Conditions
InfertilityPolyp UterusMyoma;UterusAdhesionHysteroscopyUterine SeptumRetained Products of Conception
Interventions
DEVICE

Hyalobarrier® gel endo

Intra-uterine application of 10ml sterile gel containing 30mg APC. It will be administered once, peroperatively immediate after the complete hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception

Trial Locations (1)

9000

University hospital Ghent, Ghent

Sponsors

Collaborators (1)

Nordic Pharma SAS
All Listed Sponsors
collaborator

Belgium Health Care Knowledge Centre

OTHER_GOV

collaborator

Nordic Pharma SAS

INDUSTRY

collaborator

Universitaire Ziekenhuizen KU Leuven

OTHER

collaborator

Universitair Ziekenhuis Brussel

OTHER

collaborator

Health, Innovation and Research Institute (HIRUZ) UZ Ghent

UNKNOWN

collaborator

University of Liege

OTHER

collaborator

UCL Bruxelles

UNKNOWN

collaborator

Jessa hospital, Hasselt

UNKNOWN

lead

University Hospital, Ghent

OTHER

NCT03880435 - HYALOBARRIER® GEL ENDO Versus no HYALOBARRIER® GEL ENDO Following Operative Hysteroscopy for Improving Reproductive Outcome in Women With Intrauterine Pathology Wishing to Become Pregnant | Biotech Hunter | Biotech Hunter